间歇性给药达拉非尼联合曲美替尼治疗转移性BRAFV600E突变甲状腺乳头状癌:两例病例报告
两例症状性、放射性碘难治性BRAFV600E突变甲状腺乳头状癌且体能状态差的患者,先接受达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次连续给药,后改为用药五周停三周的间歇方案;两例均快速临床改善,间歇给药后耐受性提高,分别自治疗开始27和18个月、自首次间歇停药15和13个月仍显示抗肿瘤活性。
要点
- 两例BRAFV600E突变放射性碘难治性甲状腺乳头状癌患者经达拉非尼联合曲美替尼治疗均快速临床改善。
- 改为用药五周停三周间歇方案后,两例患者均报告治疗耐受性改善。
- 自治疗开始27和18个月、自首次间歇停药15和13个月,两例仍显示抗肿瘤活性。
核心结论
- 在这两例连续患者中实现持久姑息支持评估达拉非尼联合曲美替尼间歇给药方案用于BRAFV600E突变甲状腺乳头状癌。
- 尚需正在进行的连续每日给药3期试验及后续间歇给药试验(如同其他癌症中所测试)来确认甲状腺癌间歇给药策略能否延缓耐药、改善耐受性并降低治疗费用。
研究设计与样本
- 两例连续病例报告:症状性、转移性、放射性碘难治性BRAFV600E突变甲状腺乳头状癌且体能状态差的患者。
主要发现
- 两例患者开始方案后均显示快速临床改善。
- 两例患者转为间歇给药方案后均报告治疗耐受性改善。
- 自治疗开始分别27和18个月、自首次间歇停药分别15和13个月,两例仍显示抗肿瘤活性证据。
关键数值与推荐
- 初始治疗为达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次,先连续每日给药,后改为用药五周停三周方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to achieve more durable response, while being better tolerated and more cost effective. PATIENTS: Two consecutive patients with symptomatic, metastatic radioactive iodine-resistant BRAFV600E mutated papillary thyroid cancer and poor performance status were treated initially with dabrafenib 150 mg twice daily plus trametinib 2 mg once daily, first in continuous daily dosing, then in a five-week-on and three-week-off schedule. RESULTS: Both patients showed rapid clinical improvement upon starting the regimen. They also noted improved tolerance of treatment upon transitioning to the intermittent dosing schedule. They continue to show evidence of antitumor activity 27 and 18 months respectively from the start of treatment and 15 and 13 months respectively from the start of the first break using intermittent dosing. CONCLUSIONS: Achieving durable palliation in these consecutive patients supports evaluating the intermittent dosing schedule of dabrafenib and trametinib in BRAFV600E mutated papillary thyroid cancer. Results of the ongoing phase 3 trial of continuous daily dosing and a subsequent trial of intermittent dosing, as is being tested in other cancers, will be needed to confirm that an intermittent dosing strategy in thyroid cancer can forestall resistant disease, improve tolerability, and decrease the cost of care.
引用
- White PS, Pudusseri A, Lee SL, et al. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports. Thyroid. 2017. PMID: 28805135. doi:10.1089/thy.2017.0106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。